Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Total Non-Current Liabilities (2019 - 2025)

Legend Biotech filings provide 7 years of Total Non-Current Liabilities readings, the most recent being $95.2 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 72.95% to $95.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $95.2 million, a 72.95% decrease, with the full-year FY2025 number at $95.2 million, down 72.95% from a year prior.
  • Total Non-Current Liabilities hit $95.2 million in Q4 2025 for Legend Biotech, down from $268.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $388.9 million in Q2 2025 to a low of $262860.0 in Q1 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $323.4 million (2023), compared with a mean of $276.2 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 143102.85% in 2022 and later crashed 72.95% in 2025.
  • Legend Biotech's Total Non-Current Liabilities stood at $124.3 million in 2021, then skyrocketed by 132.36% to $288.9 million in 2022, then surged by 31.83% to $380.8 million in 2023, then decreased by 7.59% to $351.9 million in 2024, then crashed by 72.95% to $95.2 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $95.2 million (Q4 2025), $268.1 million (Q3 2025), and $388.9 million (Q2 2025) per Business Quant data.